Healthcare payments have emerged as an unexpected battleground in the fight against money laundering. Traditionally associated with billing fraud and abuse, claims processors, telehealth billing platforms and pharmaceutical payment networks are now being exploited to move illicit funds under the cover of legitimate medical transactions.
According to Flagright, what was once viewed primarily as a fraud challenge has evolved into a serious Anti-Money Laundering (AML) risk that compliance teams can no longer afford to overlook.
In 2025, US enforcement action underscored the scale of the problem. The Department of Justice (DOJ) announced its largest-ever healthcare fraud takedown, charging 324 individuals in schemes involving $14.6bn in false claims. Crucially, these cases did not stop at fraud. Investigators alleged that proceeds were systematically laundered through shell companies, cryptocurrency channels and international transfers. In one instance, an international network allegedly billed Medicare $10.6bn for fraudulent medical equipment and moved more than $900m in proceeds through offshore entities and digital assets. The message from regulators was unmistakable: healthcare financial flows are being weaponised for laundering at scale.
Regulatory scrutiny has intensified accordingly. The Financial Crimes Enforcement Network (FinCEN) reported a surge in suspicious activity reports linking healthcare fraud proceeds to wider laundering networks, including foreign money laundering organisations. At the same time, the Department of Health and Human Services (HHS) has emphasised the use of advanced data analytics to identify anomalies in claims and payments, signalling that healthcare operators must treat AML risks with the same seriousness as billing fraud. For payment platforms embedded in the health ecosystem, this represents a structural shift in expectations.
Cross-border pharmaceutical transactions have also attracted attention from international watchdogs. Trade-based money laundering typologies involving inflated invoices, shell distributors and abrupt shifts in trading activity have been highlighted by global bodies. In parallel, sanctions enforcement has demonstrated how pharmaceutical and online pharmacy networks can become conduits for narcotics trafficking and illicit finance. Complex third-party payment chains, particularly those involving high-risk jurisdictions, create fertile ground for abuse if screening and due diligence controls are weak.
Within healthcare payment platforms, several risk surfaces demand urgent remediation. Fraudulent provider payouts remain a core vulnerability, where fake clinics or corrupt actors submit inflated claims and rapidly layer the funds through accounts and crypto assets. Refund and reimbursement processes can also be manipulated, with criminals using overpayments and redirected refunds to “clean” illicit funds. Meanwhile, pharmaceutical supply chains are exposed to mis-invoicing and price manipulation schemes that disguise value transfers as legitimate trade. Sanctions exposure further compounds the risk where third-party intermediaries obscure the true origin or destination of funds.
A common concern among healthcare operators is whether privacy rules restrict proactive monitoring. In practice, the HIPAA Privacy Rule permits the use of protected health information for fraud detection and compliance activities under “health care operations”. This creates a clear legal pathway for analytics-driven AML monitoring, provided that minimum necessary standards, role-based access and audit logging are strictly applied. Rather than serving as a barrier, privacy compliance and AML controls must operate in tandem.
To respond effectively, healthcare-focused FinTech platforms are adopting advanced compliance capabilities. Behavioural analytics and anomaly detection tools can establish baseline billing patterns and flag deviations in real time. Continuous sanctions and watchlist screening across all counterparties reduces exposure to prohibited entities. Targeted rules, particularly around refund activity and rapid fund movements, address known laundering typologies. Secure, audit-ready case management systems ensure that investigations involving sensitive data remain compliant and defensible.
Far from being a mere regulatory burden, strengthened AML frameworks can deliver competitive advantages. Robust controls help preserve banking partnerships, reduce fraud losses and demonstrate resilience during regulatory reviews. In a sector built on trust, visible commitment to financial integrity enhances brand reputation and long-term viability.
Healthcare payments are no longer a peripheral concern in AML strategy. They sit squarely within the modern financial crime landscape. By addressing vulnerabilities now and embedding intelligent monitoring into their platforms, healthtech billing and pharmaceutical payment operators can protect both patient funds and their own future in an increasingly scrutinised environment.
Copyright © 2026 FinTech Global
